Despite updated guidance from the American Association for the Study of Liver Diseases (AASLD) on the prevention, diagnosis, and treatment of chronic hepatitis B virus (HBV), early detection and implementation of effective treatment remains a challenge.
The first episode of this CMEOcast series on community-based efforts to improve screening and treatment of HBV will guide primary care clinicians through optimal strategies to screen for HBV in at-risk patients and utilize serological test results to drive guideline-directed care.
At the end of this CME/CE activity, participants should be able to implement routine screening protocols for HBV in the primary care setting and utilize results to drive guideline-directed care
The following learning objectives pertain only to those requesting CNE or CPE credit: Summarize routine screening protocols for HBV in the primary care setting
Supported by an educational grant from Gilead Sciences, Inc.
Primary care physicians, OB/GYNs, ED physicians, PAs, nurse practitioners, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kowdley reports that he receives research support from Conatus Pharmaceuticals Inc.; CymaBay Therapeutics; Enanta Pharmaceuticals, Inc.; Genfit; Gilead Sciences, Inc.; GlaxoSmithKline; HighTide Therapeutics Inc.; Intercept Pharmaceuticals, Inc.; and Zydus Pharmaceuticals, Inc. He is on the advisory committee for Assembly Biosciences, Inc.; Blade Therapeutics; Boehringer Ingelheim; Merck & Co., Inc.; and Roche. He is on the speakers bureau for AbbVie Inc.; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.
Dr. Wang reports that she receives grants from Gilead Sciences, Inc.
Kashemi Rorie, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-167-H01-P.
Call us at 877.CME.PROS (877.263.7767).